Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of α3 integrin and MMP-2 expression and activity

International Journal of Oncology

Volumn 33, Issue 2, 2008, Pages 405-413

  Moretti, Robert M ^a   Marelli, Marina Montagnani ^a   Mai, Stefania ^a   LimontaI, Patrizia ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Gonadotropin releasing hormone; Integrins; Invasion; Matrix metalloproteinase 2; Melanoma; Migration

Indexed keywords

ALPHA3 INTEGRIN; GELATINASE A; GONADORELIN AGONIST;

ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; CUTANEOUS MELANOMA; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 48749103313     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000022     Document Type: Article

References (60)

1. Demierre MF: Epidemiology and prevention of cutaneous melanoma. Curr Treat Options Oncol 7: 181-186, 2006.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
3. Garbe C: Cutaneous melanoma: baseline and ongoing laboratory evaluation. Dermatol Ther 18: 413-421, 2005.
4. Pharis DB: Cutaneous melanoma: therapeutic lymph node and elective lymph node dissections, lymphatic mapping, and sentinel lymph node biopsy. Dermatol Ther 18: 397-406, 2005.
5. Khayat D, Bernard-Marty C, Meric JB and Rixe O: Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol 20: 2045-2052, 2002.
6. Mandarà M, Nortilli R, Sava T and Cetto GL: Chemotherapy for metastatic melanoma. Expert Rev Anticancer Ther 6: 121-130, 2006.
7. Parmiani G, Castelli C, Santinami M and Rivoltini L: Melanoma immunology: past, present and future. Curr Opin Oncol 19: 121-127, 2007.
8. Sasse AD, Sasse EC, Clark LG, Ulloa L and Clark OA: Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 24: CD005413, 2007.
9. Tsuji T, Kawada Y, Kai-Murozono M, Komatsu S, Han SA, Takeuchi K, Mizushima H, Miyazaki K and Irimura T: Regulation of melanoma cell migration and invasion by laminin-5 and α3β1 integrin (VLA-3). Clin Exp Metastasis 19: 127-134, 2002.
10. Kuphal S, Bauer R and Bosserhoff AK: Integrin signaling in malignant melanoma. Cancer Metastasis Rev 24: 195-222, 2005.
11. Bosserhoff AK: Novel biomarkers in malignant melanoma. Clin Chim Acta 367: 28-35, 2006.
12. Watson-Hurst K and Becker D: The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther 5: 1375-1382, 2006.
13. Hofmann UB, Westphal JR, van Muijen GNP and Ruiter DJ: Matrix metalloproteinases in human melanoma. J Invest Dermatol 115: 337-344, 2000.
14. Redondo P, Lloret P, Idoate M and Inogest S: Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression. Clin Exp Dermatol 30: 541-545, 2005.
15. Nyormoi O and Bar-Eli M: Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis 20: 251-263, 2003.
16. Dadras SS and Detmar M: Angiogenesis and lymphangiogenesis of skin cancers. Hematol Oncol Clin North Am 18: 1059-1070, 2004.
17. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
18. Schally AV: Hypothalamic hormones: from neuroendocrinology to cancer therapy. Anticancer Drugs 5: 115-130, 1994.
19. Covens A, Thomas G, Shaw P, Ackerman I, Osborne R, Lukka H, Carey M, Fraussen E and Rochie K: A phase II study of leuprolide in advanced/ recurrent endometrial cancer. Gynecol Oncol 64: 126-129, 1997.
20. Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J and Candas B: Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 26: 361-379, 2005.
21. Engel JB and Schally AV: Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3: 157-167, 2007.
22. Tan SH and Wolff AC: Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer. Clin Breast Cancer 7: 455-464, 2007.
23. Limonta P, Montagnani Marelli M and Moretti RM: LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Exp Opin Invest Drugs 10: 709-720, 2001.
24. Grundker C, Gunthert AR, Westphalen S and Emons G: Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 146: 1-14, 2002.
25. Limonta P, Moretti RM, Montagnani Marelli M and Motta M: The biology of gonadotropin-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol 24: 279-295, 2003.
26. Harrison GS, Wierman ME, Nett TM and Glode LM: Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer 11: 725-748, 2004.
27. Montagnani Marelli M, Moretti RM, Januszkiewicz-Caulier J, Motta M and Limonta P: Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? Curr Cancer Drug Targets 6: 257-269, 2006.
28. Moretti RM, Montagnani Marelli M, van Groeninghen JC and Limonta P: Locally expressed luteinizing hormone-releasing hormone (LHRH) receptors mediate the oncostatic and anti-metastatic activity of LHRH agonists on melanoma cells. J Clin Endocrinol Metab 87: 3791-3797, 2002.
29. van Muijen GNP, Cornelissen IMHA, Jansen CFJ, Figdor CG, Johnson JP, Brocker EB and Ruiter DJ: Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis 9: 259-272, 1991.
30. Montagnani Marelli M, Moretti RM, Mai S, Procacci P and Limonta P: Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 30: 261-271, 2007.
31. Hofmann UB, Westphal JR, Waas ET, Zendman AJW, Cornelissen IMHA, Ruiter DJ and van Muijen GNP: Matrix metalloproteinases in human cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 81: 774-782, 1999.
32. Banerji A, Chakraborti J, Mitra A and Chatterjee A: Cell membrane-associated MT1-MMP-dependent activation of pro-MMP-2 in A375 melanoma cells. J Environ Pathol Toxicol Oncol 24: 3-17, 2005.
33. Vaisanen A, Tuominen H, Kallioinen M and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (72 kDa type IV collagenase) expression occurs in the early stage of human melanocytic tumor progression and may have prognostic value. J Pathol 80: 283-289, 1996.
34. Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ and van Muijen GN: Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression. J Pathol 191: 245-256, 2000.
35. Simonetti O, Lucarini G, Brancorsini D, Nita P, Bernardini ML, Biagini G and Offidani A: Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions. Cancer 95: 1963-1970, 2002.
36. Vaisanen AH, Kallioinen M and Turpeenniemi-Hujanen T: Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma. Hum Pathol 39: 377-385, 2008.
37. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Westphal G, Halmos G and Engel JB: Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue. Cancer Res 65: 5857-5863, 2005.
38. Dondi D, Moretti RM, Montagnani Marelli M, Pratesi G, Polizzi D, Milano M, Motta M and Limonta P: Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer 76: 506-511, 1998.
39. Limonta P, Dondi D, Moretti RM, Maggi R and Motta M: Anti-proliferative effects of luteinizing hormone releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75: 207-212, 1992.
40. Limonta P, Dondi D, Moretti RM, Fermo D, Garattini E and Motta M: Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 76: 797-800, 1993.
41. Dondi D, Limonta P, Moretti RM, Montagnani Marelli M, Garattini E and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54: 4091-4095, 1994.
42. Limonta P, Moretti RM, Montagnani Marelli M, Dondi D, Parenti M and Motta M: The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140: 5250-5256, 1999.
43. Moretti RM, Montagnani Marelli M, Dondi D, Poletti A, Martini L, Motta M and Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81: 3930-3937, 1996.
44. Montagnani Marelli M, Moretti RM, Dondi D, Motta M and Limonta P: Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140: 329-334, 1999.
45. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN and Leung HY: Evidence that prostate gonadotropin-releasing hormone receptors mediate an antitumorigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 206: 205-213, 2005.
46. Miller WR, Scott WN, Morris R, Fraser HM and Sharpe R: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 313: 231-233, 1985.
47. Harris N, Dutlow C, Eidne K, Dong KW, Roberts J and Millar R: Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Res 51: 2577-2581, 1991.
48. Cheng CK and Leung PC: Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 26: 283-306, 2005.
49. Grundker C and Emons G: Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 1: 65-71, 2003.
50. Kim KY, Choi KC, Auersperg N and Leung PC: Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 13: 211-220, 2006.
51. Cheung LWT, Leung PCK and Wong AST: Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 66: 10902-10910, 2006.
52. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G and Engel JB: Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clin Cancer Res 11: 5549-5557, 2005.
53. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G and Engel JB: Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. Eur J Cancer 41: 2196-2202, 2005.
54. Szepeshazi K, Schally AV and Halmos G: LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int J Oncol 30: 1485-1492, 2007.
55. van Groeninghen JC, Kiesel L, Winkler D and Zwirner M: Effects of luteinising hormone-releasing hormone on nervous-system tumours. Lancet 352: 372-373, 1998.
56. Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D and Hauschild A: Molecular targeted therapy for melanoma. Cancer 107: 2317-2327, 2006.
57. Kirkwood JM, Moschos S and Wang W: Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 12: 2331s-2336s, 2006.
58. Kalinsky K and Haluska FG: Novel inhibitors in the treatment of metastatic melanoma. Expert Rev Anticancer Ther 7: 715-724, 2007.
59. Gray-Schopfer V, Wellbrock C and Marais R: Melanoma biology and new targeted therapy. Nature 445: 851-857, 2007.
60. Lejeune FJ, Rimoldi D and Speiser D: New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Rev Anticancer Ther 7: 701-713, 2007.